Invasive Bladder Carcinoma — Trials

Invasive Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

179 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 95
Recruiting: 59
Ph III recruiting: 12
Growth YoY: +28.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 58.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05581589	Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer	terminated	Phase 2	4	University of WashingtonOTHER	1	Apr 27, 2026	clinicaltrials
NCT04871529	Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)	terminated	Phase 2	6	SWOG Cancer Research NetworkNETWORK